Novartis AG expected to post earnings of $2.27 a share - Earnings Preview
Novartis AG expected to post earnings of $2.27 a share - Earnings Preview
Novartis AG NOVN.S is expected to show a rise in quarterly revenue when it reports results on October 27 for the period ending September 30 2026
The Basel Basel-stadt-based company is expected to report a 4.8% increase in revenue to $14.582 billion from $13.91 billion a year ago, according to the mean estimate from 13 analysts, based on LSEG data. (Majority Sales represents Net Sales)
LSEG's mean analyst estimate for Novartis AG is for earnings of $2.27 per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 10 "strong buy" or "buy," 15 "hold" and 3 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Novartis AG is CHF128.40, about 0.4% below its last closing price of CHF128.88
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2026 | 2.27 | 2.27 | 2.41 | Beat | 6.3 |
Mar. 31 2026 | 2.15 | 2.13 | 1.99 | Missed | -6.7 |
Dec. 31 2025 | 1.99 | 1.99 | 2.03 | Beat | 1.8 |
Sep. 30 2025 | 2.27 | 2.25 | 2.25 | Met | -0.1 |
Jun. 30 2025 | 2.40 | 2.36 | 2.42 | Beat | 2.6 |
Mar. 31 2025 | 2.11 | 2.10 | 2.28 | Beat | 8.7 |
Dec. 31 2024 | 1.82 | 1.83 | 1.98 | Beat | 8.2 |
Sep. 30 2024 | 1.95 | 1.95 | 2.06 | Beat | 5.9 |
This summary was machine generated October 23 at 07:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Novartis AG
See all newsNovartis AG expected to post earnings of $2.27 a share - Earnings Preview
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination (updated)
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
Brief: Novartis Receives European Commission Approval For Cosentyx
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant